We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In a sub-analysis of the CAROLINA cardiovascular outcome trial, linagliptin demonstrated no increased cardiovascular risk versus glimepiride in Asian adults with type 2 diabetes and high cardiovascular risk.